
There are many reasons to smile in the Swedish biotech firm Hansa Biopharma these days.
The company recently announced a license agreement with US-based gene therapy firm Sarepta giving the US company license to develop the Swedish company’s main asset, imlifidase, as a potential pre-treatment for certain patients prior to gene therapy in two rare diseases.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app